Cite
Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection.
MLA
Kim, Deok-Hwan, et al. “Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects HACE2 TG Mice against Lethal SARS-CoV-2 Infection.” Vaccines, vol. 12, no. 8, Aug. 2024, p. 921. EBSCOhost, https://doi.org/10.3390/vaccines12080921.
APA
Kim, D.-H., Lee, J., Lee, D.-Y., Lee, S.-H., Jeong, J.-H., Kim, J.-Y., Kim, J., Choi, Y.-K., Lee, J.-B., Park, S.-Y., Choi, I.-S., Lee, S.-W., Youk, S., & Song, C.-S. (2024). Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection. Vaccines, 12(8), 921. https://doi.org/10.3390/vaccines12080921
Chicago
Kim, Deok-Hwan, Jiho Lee, Da-Ye Lee, Seung-Hun Lee, Jei-Hyun Jeong, Ji-Yun Kim, Jiwon Kim, et al. 2024. “Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects HACE2 TG Mice against Lethal SARS-CoV-2 Infection.” Vaccines 12 (8): 921. doi:10.3390/vaccines12080921.